Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Sell
40
VMD Quote, Financials, Valuation and Earnings
Last price:
$6.65
Seasonality move
:
2.27%
Day range:
$6.48 - $6.66
52-week range:
$6.14 - $9.81
Dividend yield:
0%
P/E ratio:
22.17x
P/S ratio:
1.17x
P/B ratio:
1.95x
Volume:
129.3K
Avg. volume:
178.2K
1-year change:
-7.64%
Market cap:
$262.8M
Revenue:
$224.3M
EPS (TTM):
$0.30
Analysts' Opinion
-
Consensus RatingViemed Healthcare has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.83, Viemed Healthcare has an estimated upside of 92.98% from its current price of $6.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $6.65.
Fair Value
-
According to the consensus of 3 analysts, Viemed Healthcare has 92.98% upside to fair value with a price target of $12.83 per share.
VMD vs. S&P 500
-
Over the past 5 trading days, Viemed Healthcare has overperformed the S&P 500 by 0.12% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Viemed Healthcare does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Viemed Healthcare has grown year-over-year revenues for 14 quarters straight. In the most recent quarter Viemed Healthcare reported revenues of $59.1M.
Earnings Growth
-
Viemed Healthcare has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Viemed Healthcare reported earnings per share of $0.06.
Enterprise value:
258.6M
EV / Invested capital:
--
Price / LTM sales:
1.17x
EV / EBIT:
13.55x
EV / Revenue:
1.11x
PEG ratio (5yr expected):
1.11x
EV / Free cash flow:
-39.91x
Price / Operating cash flow:
195.44x
Enterprise value / EBITDA:
5.77x
Gross Profit (TTM):
$136.7M
Return On Assets:
7.28%
Net Income Margin (TTM):
5.28%
Return On Equity:
9.69%
Return On Invested Capital:
9.27%
Operating Margin:
2.49%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $146.1M | $194M | $232.8M | $50.6M | $59.1M | |
| Gross Profit | $88.9M | $118.6M | $136.7M | $29.8M | $33.3M | |
| Operating Income | $8.3M | $15.5M | $15.1M | $2.4M | $1.5M | |
| EBITDA | $25M | $38.5M | $44.8M | $8.6M | $10.5M | |
| Diluted EPS | $0.15 | $0.25 | $0.30 | $0.04 | $0.06 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $48.3M | $47.8M | $46.7M | $38.6M | $49.1M | |
| Total Assets | $113M | $119M | $124.6M | $154.9M | $178.1M | |
| Current Liabilities | $21.9M | $17.7M | $23.4M | $30.1M | $35.5M | |
| Total Liabilities | $29.6M | $23M | $24.6M | $38.6M | $41.3M | |
| Total Equity | $83.4M | $96M | $100M | $116.3M | $136.7M | |
| Total Debt | $7.2M | $5.3M | -- | $6.5M | $3.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $31.1M | $35.9M | $40.8M | $1.2M | $2.9M | |
| Cash From Investing | -$24.1M | -$53.6M | -$33.9M | -$5.4M | -$8.5M | |
| Cash From Financing | -$12.7M | $1.4M | -$4.1M | -$1.3M | -$1.7M | |
| Free Cash Flow | $7.5M | $8.5M | -$6.5M | -$4.8M | -$12.6M | |
VMD
Sector
Market Cap
$262.8M
$33.4M
Price % of 52-Week High
67.79%
45.25%
Dividend Yield
0%
0%
Shareholder Yield
0.81%
-0.66%
1-Year Price Total Return
-7.64%
-40%
Beta (5-Year)
1.492
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.60
200-day SMA
Sell
Level
$7.80
Bollinger Bands (100)
Sell
Level
6.81 - 8.03
Chaikin Money Flow
Sell
Level
-965.5K
20-day SMA
Sell
Level
$6.77
Relative Strength Index (RSI14)
Sell
Level
46.10
ADX Line
Sell
Level
19.04
Williams %R
Neutral
Level
-47.2076
50-day SMA
Sell
Level
$6.87
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Neutral
Level
7.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.6993)
Buy
CA Score
(Annual)
Level (1.6229)
Buy
Beneish M-Score
(Annual)
Level (-2.8702)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.1737)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
Stock Forecast FAQ
In the current month, VMD has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VMD average analyst price target in the past 3 months is $12.83.
-
Where Will Viemed Healthcare Stock Be In 1 Year?
According to analysts, the consensus estimate is that Viemed Healthcare share price will rise to $12.83 per share over the next 12 months.
-
What Do Analysts Say About Viemed Healthcare?
Analysts are divided on their view about Viemed Healthcare share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Viemed Healthcare is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Viemed Healthcare's Price Target?
The price target for Viemed Healthcare over the next 1-year time period is forecast to be $12.83 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is VMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Viemed Healthcare is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VMD?
You can purchase shares of Viemed Healthcare via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Viemed Healthcare shares.
-
What Is The Viemed Healthcare Share Price Today?
Viemed Healthcare was last trading at $6.65 per share. This represents the most recent stock quote for Viemed Healthcare. Yesterday, Viemed Healthcare closed at $6.65 per share.
-
How To Buy Viemed Healthcare Stock Online?
In order to purchase Viemed Healthcare stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
